Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 8, 2025

Primary Completion Date

July 30, 2025

Study Completion Date

December 15, 2025

Conditions
B-precursor Acute Lymphoblastic Leukemia
Interventions
DRUG

Blinatumomab

IV infusion

Trial Locations (6)

010-8543

Akita University Hospital, Akita

812-8582

Kyushu University Hospital, Fukuoka

830-0011

Kurume University Hospital, Kurume-shi

960-1295

Fukushima Medical University Hospital, Fukushima

920-8641

Kanazawa University Hospital, Kanazawa

990-9585

Yamagata University Hospital, Yamagata

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY